Immunotherapy for newly diagnosed glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new personalized immunotherapy (DOC1021) for people with newly diagnosed glioblastoma. The treatment uses your own immune cells to attack the tumor and is given after surgery and with standard chemotherapy and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a newly diagnosed glioblastoma that can be mostly removed with surgery (at least 70% of the visible tumor).
- You must be able to receive standard chemotherapy (temozolomide) and radiation after surgery.
- You must have adequate kidney, liver and bone marrow function (checked with blood tests).
- You must be able to tolerate the study procedures, including a blood cell collection (leukapheresis) and three injections of the immunotherapy near lymph nodes in your neck.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
This trial tests a personalized vaccine (made from your own immune cells and tumor 'neoantigens') combined with the chemotherapy drug temozolomide for people with newly diagnosed glioblastoma. The goal is to see if adding the vaccine helps the immune system better fight the tumor.
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.